A Study to Test the Effect of BI 456906 on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

Overview

About this study

The purpose of this trial is to evaluate the effect of treatment with BI 456906 3.6 and 6.0 mg once weekly versus (vs.) placebo on cardiovascular (CV) safety as an adjunct to standard of care for CV risk reduction, a reduced-calorie diet, and increased physical activity in trial participants with body mass index (BMI) ≥27 kg/m^2 with either established cardiovascular disease (CVD) or chronic kidney disease (CKD), and/or at least 2 weight-related complications or risk factors for CVD.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

1. Male or female, age ≥ 18 years at the time of signing informed consent, and at least
the legal age of consent in countries where it is > 18 years.

2. Body mass index (BMI) ≥ 27 kg/m^2 at screening with established cardiovascular disease
(CVD) and/or at least 2 weight-related complications or risk factors for CVD OR BMI
≥ 30 kg/m^2 at screening with established CVD or chronic kidney disease (CKD), and/or at
least 2 weight-related complications or risk factors for CVD.

Exclusion Criteria:

1. Previous treatment with glucagon-like peptide-1 receptor (GLP-1R) agonists within 3
months before screening.

2. Type 1 diabetes.

3. Less than 3 months between the last dose of GLP-1R agonists and GLP-1R
agonist/insulin/glucose-dependent insulinotropic polypeptide (GIP) combinations and
screening.

4. Known clinically significant gastric emptying abnormality (e.g., severe diabetic
gastroparesis or gastric outlet obstruction).

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/5/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Andres Acosta, M.D., Ph.D.

Open for enrollment

Contact information:

Jessica Stutzman

Stutzman.Jessica@mayo.edu

More information

Publications

Publications are currently not available